KM 11060 structure
|
Common Name | KM 11060 | ||
---|---|---|---|---|
CAS Number | 774549-97-2 | Molecular Weight | 422.328 | |
Density | 1.5±0.1 g/cm3 | Boiling Point | 607.3±65.0 °C at 760 mmHg | |
Molecular Formula | C19H17Cl2N3O2S | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | 321.1±34.3 °C | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of KM 11060KM11060 is a novel corrector of the F508del-CFTR trafficking defect.Target: CFTRin vitro: Small-molecule correctors such as KM11060 may serve as useful pharmacological tools in studies of the F508del-CFTR processing defect and in the development of cystic fibrosis therapeutics. KM11060 rescues F508del-CFTR trafficking in cultured cells and native epithelial tissues. KM11060 partially corrects F508del-CFTR processing and increases surface expression to 75% of that observed in cells incubated at low temperature. Up to 50% of the F508del-CFTR in cells treated with KM11060 was complex-glycosylated, indicating passage through the Golgi. KM11060 as a promising compound for further development of CF therapeutics. [1]in vivo: In LPS-induced acute lung inflammation, blockade of PSGL-1 (P-selectin glycoprotein ligand-1) or P-selectin, antagonism of PAF by WEB2086, or correction of mutated CFTR trafficking by KM11060 could significantly increase plasma lipoxin A4 levels in F508del relevant to wildtype mice. [2] |
Name | 7-chloro-4-[4-(4-chlorophenyl)sulfonylpiperazin-1-yl]quinoline |
---|---|
Synonym | More Synonyms |
Description | KM11060 is a novel corrector of the F508del-CFTR trafficking defect.Target: CFTRin vitro: Small-molecule correctors such as KM11060 may serve as useful pharmacological tools in studies of the F508del-CFTR processing defect and in the development of cystic fibrosis therapeutics. KM11060 rescues F508del-CFTR trafficking in cultured cells and native epithelial tissues. KM11060 partially corrects F508del-CFTR processing and increases surface expression to 75% of that observed in cells incubated at low temperature. Up to 50% of the F508del-CFTR in cells treated with KM11060 was complex-glycosylated, indicating passage through the Golgi. KM11060 as a promising compound for further development of CF therapeutics. [1]in vivo: In LPS-induced acute lung inflammation, blockade of PSGL-1 (P-selectin glycoprotein ligand-1) or P-selectin, antagonism of PAF by WEB2086, or correction of mutated CFTR trafficking by KM11060 could significantly increase plasma lipoxin A4 levels in F508del relevant to wildtype mice. [2] |
---|---|
Related Catalog | |
References |
Density | 1.5±0.1 g/cm3 |
---|---|
Boiling Point | 607.3±65.0 °C at 760 mmHg |
Molecular Formula | C19H17Cl2N3O2S |
Molecular Weight | 422.328 |
Flash Point | 321.1±34.3 °C |
Exact Mass | 421.041840 |
PSA | 61.89000 |
LogP | 4.19 |
Vapour Pressure | 0.0±1.7 mmHg at 25°C |
Index of Refraction | 1.676 |
Storage condition | 2-8℃ |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
Personal Protective Equipment | Eyeshields;Faceshields;Gloves;type P2 (EN 143) respirator cartridges |
RIDADR | UN 2811 6.1 / PGIII |
HS Code | 2935009090 |
Precursor 3 | |
---|---|
DownStream 0 |
HS Code | 2935009090 |
---|---|
Summary | 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0% |
Important role of platelets in modulating endotoxin-induced lung inflammation in CFTR-deficient mice.
PLoS ONE 8 , e82683, (2013) Mutation of CFTR (cystic fibrosis transmembrane conductance regulator) leads to cystic fibrosis (CF). Patients with CF develop abnormalities of blood platelets and recurrent lung inflammation. However... |
7-Chloro-4-{4-[(4-chlorophenyl)sulfonyl]-1-piperazinyl}quinoline |
Quinoline, 7-chloro-4-[4-[(4-chlorophenyl)sulfonyl]-1-piperazinyl]- |
7-chloro-4-{4-[(4-chlorophenyl)sulfonyl]piperazin-1-yl}quinoline |
7-chloro-4-{4-[(4-chlorophenyl)sulfonyl]piperazino}quinoline |
KM 11060 |
KM11060 |